KR20190095936A - 인테그린 저해제로의 위장관 질환의 치료 - Google Patents

인테그린 저해제로의 위장관 질환의 치료 Download PDF

Info

Publication number
KR20190095936A
KR20190095936A KR1020197020004A KR20197020004A KR20190095936A KR 20190095936 A KR20190095936 A KR 20190095936A KR 1020197020004 A KR1020197020004 A KR 1020197020004A KR 20197020004 A KR20197020004 A KR 20197020004A KR 20190095936 A KR20190095936 A KR 20190095936A
Authority
KR
South Korea
Prior art keywords
integrin inhibitor
subject
disease
reservoir
location
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197020004A
Other languages
English (en)
Korean (ko)
Inventor
미첼 로렌스 존스
샤랏 싱
크리스토퍼 로렌 월
해리 스틸리
Original Assignee
프로제너티, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로제너티, 인크. filed Critical 프로제너티, 인크.
Publication of KR20190095936A publication Critical patent/KR20190095936A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/07—Endoradiosondes
    • A61B5/073—Intestinal transmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
    • A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178—Lectin superfamily, e.g. selectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0097—Micromachined devices; Microelectromechanical systems [MEMS]; Devices obtained by lithographic treatment of silicon; Devices comprising chips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A61B2010/0061—Alimentary tract secretions, e.g. biliary, gastric, intestinal, pancreatic secretions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/02—Details of sensors specially adapted for in-vivo measurements
    • A61B2562/0233—Special features of optical sensors or probes classified in A61B5/00
    • A61B2562/0238—Optical sensor arrangements for performing transmission measurements on body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Cell Biology (AREA)
KR1020197020004A 2016-12-14 2017-12-14 인테그린 저해제로의 위장관 질환의 치료 Ceased KR20190095936A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662434369P 2016-12-14 2016-12-14
US62/434,369 2016-12-14
US201762478863P 2017-03-30 2017-03-30
US62/478,863 2017-03-30
US201762545220P 2017-08-14 2017-08-14
US62/545,220 2017-08-14
US201762583804P 2017-11-09 2017-11-09
US62/583,804 2017-11-09
PCT/US2017/066441 WO2018112215A1 (en) 2016-12-14 2017-12-14 Treatment of a disease of the gastrointestinal tract with an integrin inhibitor

Publications (1)

Publication Number Publication Date
KR20190095936A true KR20190095936A (ko) 2019-08-16

Family

ID=60953955

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197020004A Ceased KR20190095936A (ko) 2016-12-14 2017-12-14 인테그린 저해제로의 위장관 질환의 치료

Country Status (11)

Country Link
US (1) US20200253506A1 (enExample)
EP (2) EP4233902A3 (enExample)
JP (1) JP7150723B2 (enExample)
KR (1) KR20190095936A (enExample)
CN (2) CN116712540A (enExample)
AU (1) AU2017376801B9 (enExample)
BR (1) BR112019012071A2 (enExample)
CA (1) CA3045931A1 (enExample)
MX (1) MX2019006867A (enExample)
TW (1) TW201834710A (enExample)
WO (1) WO2018112215A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3723801B9 (en) * 2017-12-14 2023-10-04 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a s1p modulator
US20200390426A1 (en) * 2017-12-22 2020-12-17 Aobiome Llc Devices and methods for microbiome sampling
WO2019246455A1 (en) * 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2020070818A1 (ja) * 2018-10-03 2020-04-09 オリンパス株式会社 内視鏡装置及び観察時間計測方法
EP3956358A4 (en) * 2019-04-17 2023-01-25 Millennium Pharmaceuticals, Inc. COMBINATION THERAPY WITH ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR
CN115666704B (zh) * 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2021126925A1 (en) * 2019-12-16 2021-06-24 Eli Lilly And Company Capsule for gastrointestinal sampling
CN117729881A (zh) * 2021-03-05 2024-03-19 光疗胶囊医学有限公司 用于胃肠位置估计的装置和方法
WO2022212510A1 (en) * 2021-04-01 2022-10-06 Medibeacon Inc. Methods of monitoring mucosal healing
JP7699774B2 (ja) * 2021-09-07 2025-06-30 公立大学法人名古屋市立大学 間質性膀胱炎・膀胱痛症候群の予防又は治療用医薬組成物
CN114659995B (zh) * 2022-05-24 2022-08-23 广东省农业科学院动物科学研究所 一种基于显微高光谱的鱼类诱食剂效果评价方法及系统
CN114907468B (zh) * 2022-06-10 2023-05-23 东莞理工学院 一种仿刺参整合素多克隆抗体、抗原蛋白及其制备方法
CN116027048A (zh) * 2023-02-06 2023-04-28 山东中鸿特检生物科技有限公司 一种细胞因子风暴综合征诊断试剂盒及其应用
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
WO2025050006A1 (en) * 2023-09-01 2025-03-06 Biora Therapeutics, Inc. Ingestible drug delivery device

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4190328A (en) 1978-12-01 1980-02-26 Levine Robert A Process for detection of blood-borne parasites
DE2928477C3 (de) * 1979-07-14 1982-04-15 Battelle-Institut E.V., 6000 Frankfurt Vorrichtung zur Freisetzung von Substanzen an definierten Orten des Verdauungstraktes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
WO1989012232A1 (en) 1988-06-08 1989-12-14 London Diagnostics, Inc. Assays utilizing sensitizer-induced production of detectable signals
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5314805A (en) 1991-10-28 1994-05-24 Molecular Probes, Inc. Dual-fluorescence cell viability assay using ethidium homodimer and calcein AM
US5596090A (en) 1992-07-24 1997-01-21 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human VCAM-1 RNA
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5763602A (en) 1996-10-01 1998-06-09 Li; Ying-Syi Methods of syntheses of phthalocyanine compounds
US5919792A (en) 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
AU6780398A (en) 1997-03-28 1998-10-22 Du Pont Merck Pharmaceutical Company, The Heterocyclic integrin inhibitor prodrugs
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6630492B1 (en) 1997-08-28 2003-10-07 Novartis Ag Lymphocyte function antigen-1 antagonists
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1078265A1 (en) 1998-02-18 2001-02-28 Dade Behring Inc. Chemiluminescent compositions for use in detection of multiple analytes
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
KR100711840B1 (ko) 1999-01-22 2007-05-02 엘란 파마슈티칼스, 인크. Ｖｌａ-4 관련 질환 치료용 아실 유도체
US8636648B2 (en) * 1999-03-01 2014-01-28 West View Research, Llc Endoscopic smart probe
US6331530B1 (en) 1999-07-13 2001-12-18 The Trustees Of Columbia University In The City Of New York Hydrophilic carrier for photosensitizers that cleaves when they catalyze the formation of singlet oxygen
US6703248B1 (en) 1999-12-15 2004-03-09 Dade Behring Marburg Gmbh Particles for diagnostic and therapeutic use
JP4039856B2 (ja) 2000-02-03 2008-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 インテグリン発現阻害剤
AU4721901A (en) 2000-02-25 2001-09-03 Immunex Corp Integrin antagonists
WO2001068586A2 (en) 2000-03-14 2001-09-20 Novartis Ag α4β1 AND α4β7 INTEGRIN INHIBITORS
US6794506B2 (en) 2000-07-21 2004-09-21 Elan Pharmaceuticals, Inc. 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
DE10040105A1 (de) 2000-08-17 2002-02-28 Merck Patent Gmbh Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften
JP2004521680A (ja) * 2001-01-22 2004-07-22 ヴイ−ターゲット テクノロジーズ リミテッド 摂取可能な装置
US7160258B2 (en) * 2001-06-26 2007-01-09 Entrack, Inc. Capsule and method for treating or diagnosing the intestinal tract
DE10204789A1 (de) 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
JP2006509183A (ja) 2002-03-05 2006-03-16 アクララ バイオサイエンシーズ， インコーポレイテッド 膜結合増感剤を用いる多重分析
NZ535425A (en) 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
PL374922A1 (en) * 2002-07-05 2005-11-14 Temrel Limited Controlled release composition
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
EP1594477A4 (en) * 2003-01-29 2009-07-15 Pill Pharma Ltd E ACTIVE MEDICATION CONTRIBUTION IN THE DIGESTIVE TUBE
DE10305784A1 (de) 2003-02-12 2004-08-26 Merck Patent Gmbh Verfahren zur Herstellug bicyclischer aromatischer Aminosäuren sowie deren Zwischenprodukte
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
JP2007506757A (ja) 2003-09-23 2007-03-22 ライト サイエンシズ コーポレイション 光線力学療法のための結合体
BRPI0414927A (pt) 2003-10-01 2006-11-07 Merck Patent Ges Mit Beschaenk antagonistas de integrina alfavbeta3 e alfavbeta6 como agentes antifibróticos
TW200524865A (en) 2003-10-08 2005-08-01 Nicholas Piramal India Ltd Fibrinogen receptor antagonists and their use
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
EP1734933B1 (en) * 2004-03-26 2010-05-26 LEK Pharmaceuticals d.d. Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)
CA2577370A1 (en) 2004-08-16 2006-03-02 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
DK176145B1 (da) 2004-09-23 2006-10-02 Guldmann V As Kobling
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE102004059613A1 (de) * 2004-12-10 2006-06-14 Liedtke, Rainer K., Dr. Zusammensetzung und Methode einer topischen Therapie von Neurodermitis
WO2006077528A2 (en) * 2005-01-18 2006-07-27 Koninklijke Philips Electronics, N.V. Electronically controlled capsule
ITMI20050328A1 (it) 2005-03-03 2006-09-04 Univ Degli Studi Milano Composti peptidomimetrici e preparazione di derivati biologicamente attivi
WO2007054128A1 (en) 2005-11-14 2007-05-18 Dominion Pharmakine S.L. Novel inhibitors of the lfa-1/icam-1 interaction, and uses thereof
GB0507918D0 (en) 2005-04-19 2005-05-25 Novartis Ag Organic compounds
AU2006251620B8 (en) 2005-05-20 2013-07-18 Elan Pharmaceuticals, Inc. Imidazolone phenylalanine derivatives as VLA-4 antagonists
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0520378D0 (en) 2005-10-06 2005-11-16 Novartis Ag Organic compounds
US7928113B2 (en) 2005-11-14 2011-04-19 University Of Southern California Integrin-binding small molecules
US8129366B2 (en) 2005-12-13 2012-03-06 Daiichi Sankyo Company, Limited VLA-4 inhibitory drug
TWI389904B (zh) 2006-02-27 2013-03-21 Elan Pharm Inc 抑制由ｖｌａ-４所調節的白血球黏附之嘧啶磺醯胺化合物
EP1989231B1 (en) 2006-03-21 2015-05-20 Genentech, Inc. Combinatorial therapy involving alpha5beta1 antagonists
EP2021373A4 (en) 2006-05-31 2010-06-02 Hanwa Chemical Corp MONOCLONAL ANTIBODY VCAM-1 SPECIFIC
EP2046434B1 (en) * 2006-06-23 2012-02-08 Koninklijke Philips Electronics N.V. Medicament delivery system
JP5362563B2 (ja) 2006-08-03 2013-12-11 アストラゼネカ・アクチエボラーグ αＶβ６に対する抗体およびその使用
CA2675827A1 (en) * 2007-02-26 2008-09-04 Duocure, Inc. Spray administration of compositions including active agents such as peptides to the gastrointestinal tract
CN103120653B (zh) * 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
CA2693863C (en) 2007-07-17 2017-10-03 Merck Patent Gmbh Engineered anti-alpha v- integrin hybrid antibodies
US20090180951A1 (en) 2007-12-12 2009-07-16 Molecular Insight Pharmaceuticals, Inc. Inhibitors of integrin vla-4
WO2011004395A1 (en) 2009-07-06 2011-01-13 Intas Biopharmaceuticals Limited Microemulsion formulation for biologicals
EP2461746A1 (en) * 2009-08-05 2012-06-13 Tel HaShomer Medical Research Infrastructure and Services Ltd. Methods and devices for providing information useful in the diagnosis of abnormalities of the gastrointestinal tract
WO2011049412A2 (en) 2009-10-23 2011-04-28 Hanwha Chemical Corporation Human recombinant monoclonal antibody that specifically binds to vcam-1 and inhibits adhesion and transmigration between leukocytes and endothelial cells
ITFI20100019A1 (it) 2010-02-12 2011-08-13 Univ Firenze Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori.
WO2011115688A2 (en) 2010-03-19 2011-09-22 H. Lee Moffitt Cancer Center & Research Institute Integrin interaction inhibitors for the treatment of cancer
CN102883750A (zh) 2010-04-30 2013-01-16 伊兰药品公司 选择性整联蛋白抑制剂
US9415004B2 (en) * 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8907081B2 (en) 2011-05-27 2014-12-09 Sharp Laboratories Of America, Inc. Long wavelength absorbing porphyrin photosensitizers for dye-sensitized solar cells
PL2744802T3 (pl) 2011-08-17 2017-07-31 Piramal Imaging Sa Związki do wiązania do glikoproteiny IIB/IIIA specyficznej wobec płytek i ich zastosowanie do obrazowania zakrzepów
FR2979346B1 (fr) 2011-08-23 2013-09-27 Univ Joseph Fourier Nanocorps anti-vcam-1
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
FR2986432B1 (fr) 2012-02-06 2014-03-14 Univ Lille Ii Droit & Sante Proteines 28kda gst provenant de schistosomes pour leur utilisation dans le traitement des maladies inflammatoires auto-immunes engendrant une reponse de type th1 et/ou th17
GB201207155D0 (en) 2012-04-24 2012-06-06 Isis Innovation Antibodies
US20140349944A1 (en) 2013-05-23 2014-11-27 Musc Foundation For Research Development Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases
JP2016520199A (ja) 2013-05-24 2016-07-11 ネステク ソシエテ アノニム 過敏性腸症候群を診断するための経路特異的マーカー
WO2015002230A1 (ja) * 2013-07-03 2015-01-08 武田薬品工業株式会社 アミド化合物
US20160235663A1 (en) * 2013-09-26 2016-08-18 Medimetrics Personalized Drug Delivery, B.V. Delivery capsule with threshold release
CN105848557B (zh) * 2013-12-27 2018-09-28 王康怀 具有多光谱光源的胶囊摄影机装置
DK3089994T3 (da) 2013-12-30 2022-07-04 Epimab Biotherapeutics Inc Fabs-in-tandem-immunglobulin og anvendelser deraf
GB201400442D0 (en) * 2014-01-10 2014-02-26 Sigmoid Pharma Ltd Compositions for use in the treatment of ulcerative colitis
WO2015112575A1 (en) 2014-01-22 2015-07-30 The Board Of Regents Of The University Of Nebraska Gastrointestinal sensor implantation system
US10955422B2 (en) * 2014-02-27 2021-03-23 Biogen Ma, Inc. Method of assessing risk of PML
DE102014004843A1 (de) 2014-04-02 2015-10-08 Schaltbau Gmbh Gleichstromschütz mit zusätzlicher Schalttauglichkeit für Wechselstromlasten und Polung entgegen der Vorzugsstromrichtung
CN106687107B (zh) * 2014-08-13 2020-12-25 西达-赛奈医疗中心 抗产甲烷组合物及其用途
DK3197336T3 (da) * 2014-09-25 2021-01-18 Progenity Inc Elektromekanisk pilleindretning med lokaliseringsegenskaber
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
WO2016099792A1 (en) * 2014-11-19 2016-06-23 Nano Pharmaceutical Laboratories Llc Wireless communications system integrating electronics into orally ingestible products for controlled release of active ingredients
CN104473611B (zh) 2015-01-19 2018-01-30 吉林大学 具有超声波定位功能的胶囊内窥镜系统
AU2016229976B2 (en) * 2015-03-06 2021-11-11 Theriva Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
WO2023091991A1 (en) 2021-11-17 2023-05-25 H2 Clipper, Inc. Improved system, method and apparatus for airship manufacture using robotics

Also Published As

Publication number Publication date
EP3554539C0 (en) 2023-06-07
AU2017376801A1 (en) 2019-06-13
EP3554539A1 (en) 2019-10-23
CN116712540A (zh) 2023-09-08
JP2020502125A (ja) 2020-01-23
EP3554539B9 (en) 2023-10-04
BR112019012071A2 (pt) 2019-11-12
CN110167589B (zh) 2023-05-16
AU2017376801B2 (en) 2024-07-11
TW201834710A (zh) 2018-10-01
CN110167589A (zh) 2019-08-23
EP4233902A3 (en) 2024-02-28
AU2017376801B9 (en) 2024-08-01
MX2019006867A (es) 2020-01-13
WO2018112215A1 (en) 2018-06-21
CA3045931A1 (en) 2018-06-21
JP7150723B2 (ja) 2022-10-11
US20200253506A1 (en) 2020-08-13
EP3554539B1 (en) 2023-06-07
EP4233902A2 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
AU2017376801B9 (en) Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
KR102616436B1 (ko) Tnf 저해제로의 위장관 질환의 치료
CN110072551B (zh) 使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病
US20240252425A1 (en) Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
US20230033021A1 (en) Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US20200323772A1 (en) Treatment of inflammatory disease using ingestible device to release immune modulator
US12227565B2 (en) Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20200315540A1 (en) Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190710

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201214

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220725

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20221004

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220725

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I